Mirum Pharmaceuticals, Inc.
MIRM
$100.64
$1.871.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.23% | 7.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.23% | 7.35% | |||
| Cost of Revenue | 5.36% | 1.91% | |||
| Gross Profit | 11.30% | 8.63% | |||
| SG&A Expenses | -15.43% | 29.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.28% | 45.31% | |||
| Operating Income | 58.68% | -1,283.03% | |||
| Income Before Tax | 91.70% | -15,811.34% | |||
| Income Tax Expenses | 255.58% | -38.07% | |||
| Earnings from Continuing Operations | 91.49% | -13,689.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 91.49% | -13,689.79% | |||
| EBIT | 58.68% | -1,283.03% | |||
| EBITDA | 65.95% | -3,835.17% | |||
| EPS Basic | 92.10% | -11,667.22% | |||
| Normalized Basic EPS | 47.77% | -1,006.31% | |||
| EPS Diluted | 92.10% | -10,806.90% | |||
| Normalized Diluted EPS | 47.77% | -1,006.31% | |||
| Average Basic Shares Outstanding | 7.69% | 17.24% | |||
| Average Diluted Shares Outstanding | 7.69% | 17.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||